Jane L Liesveld MD

Hematologic Oncology

Professor of Medicine and Hematology/Oncology and an attending hematologist at the University of Rochester Medical Center

Join to View Full Profile

601 Elmwood Ave# BoxRochester, NY 14642
Phone+1 585-275-0784
Fax+1 585-273-5761

Education & Training

University of Rochester Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1988
University of Rochester Medical CenterFellowship, Hematology and Medical Oncology, 1984 - 1987
St Marys CampusFellowship, Hematology, 1983 - 1984
University of Rochester Medical CenterResidency, Internal Medicine, 1980 - 1983
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1980

Certifications & Licensure

IA State Medical License 1981 - 2027
NY State Medical License 1981 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Bortezomib in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2005 May 01
Completed
Phase 2
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer Start of enrollment: 2001 Aug 01
Completed
Phase 2
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Jan 01
Completed
Phase 1
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
Roles: Contact, Principal Investigator
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients Start of enrollment: 2014 Mar 01
Completed
Phase 1, Phase 2
Umbilical Cord Blood Transplantation From Unrelated Donors
RECRUITING
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML.
Negar Khazan, Cameron Wa Snyder, Chandhana Ravi, Elizabeth Lamere, Niloy A Singh
Biorxiv. 2025-10-02
9 citations
Taurine from tumour niche drives glycolysis to promote leukaemogenesis.
Sonali Sharma, Benjamin J Rodems, Cameron D Baker, Christina M Kaszuba, Edgardo I Franco
Nature. 2025-08-01
Taurine Transporter SLC6A6 Expression Promotes Mesenchymal Stromal Cell Function.
Christina M Kaszuba, Sonali Sharma, Benjamin J Rodems, Cameron D Baker, Palomi Schacht
Biorxiv. 2025-06-27

Abstracts/Posters

Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int...
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic ...
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Ov...
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
2012 Best of ASCO Chicago
American Society of Clinical Oncology(ASCO), Chicago, Illinois - 7/12/2012

Press Mentions

Energy Drink Ingredient Taurine Found to Help Blood Cancer Cells GrowMay 17th, 2025
HMN 2025: How It Can Drive Leukemia Progress by Aiding Cancer Cell MetabolismMay 15th, 2025
A Downside of Taurine: It Drives Leukemia GrowthMay 14th, 2025
Join now to see all

Grant Support

Mechanisms of marrow microenvironmental aging and their impact of progression of clonal hematopoiesisUNIVERSITY OF ROCHESTER2022–2027
Substrata Interactions Of Normal And Leukemic Hematopoietic Stem CellsNational Cancer Institute2008–2009
Proteasome Inhibition In Myelodysplastic SyndromesNational Cancer Institute2005–2006
Progenitor Cell-Microenvironment InteractionsNational Heart, Lung, And Blood Institute1990–1994